US Patent No: 7,125,689

Number of patents in Portfolio can not be more than 2000

Method for rendering streptokinase less immunogenic to a human

ALSO PUBLISHED AS: 20030153043

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Protein, or parts of proteins, may be rendered non-immunogenic, or less immunogenic, to a given species by identifying in their amino acid sequences one or more potential epitopes for T-cells of the given species and modifying the amino acid sequence to eliminate at least one of the T-cell epitopes. This eliminates or reduces the immunogenicity of the protein when exposed to the immune system of the given species. Monoclonal antibodies and other immunoglobulin-like molecules can particularly benefit from being de-immunised in this way: for example, mouse-derived immunoglobulins can be de-immunised for human therapeutic use.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MERCK PATENT GMBHDARMSTADT1956

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Adair, Fiona Suzanne Aberdeen, GB 3 11
Carr, Francis Joseph Aberdeen, GB 26 118
Carter, Graham Aberdeen, GB 25 97
Hamilton, Anita Anne Aberdeen, GB 3 11

Cited Art Landscape

Patent Info (Count) # Cites Year
 
CENTRO DE INMUNOLOGIA MOLECULAR (1)
* 5,712,120 Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them 45 1995
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PRECISION BIOLOGICS, INC. (5)
7,314,622 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 4 2006
7,829,678 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 2 2008
8,535,667 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 0 2010
8,524,456 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 0 2010
8,802,090 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 0 2011
 
NEOGENIX ONCOLOGY, INC. (1)
7,763,720 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 1 2007
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 24, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00